СибНСХБ

Вид поиска

Область поиска

Найдено в других БД

Формат представления найденных документов:
библиографическое описание	краткий	полный

Отсортировать найденные документы по:
автору	заглавию	году издания	типу документа

Поисковый запрос: (<.>S=ДИГИДРОКСИВИТАМИН D[3]*1'АЛЬФА',25-<.>)

Общее количество найденных документов : 4
Показаны документы с 1 по 4

РЖ ВИНИТИ 34 (BI48) 96.07-04Т2.97

Farach-Carson, Mary C.
Controlling the nongenomic actions of 1,25(OH)[2]D[3] [Text] / Mary C. Farach-Carson, Robert E. Devoll // News Physiol. Sci. - 1995. - Vol. 10, N oct. - P198-204 . - ISSN 0886-1714
Перевод заглавия: Регулирование внегеномных эффектов 1,25 (OH)[2]D[3]
Аннотация: The active hormonal form of vitamin D (1'альфа', 25-dihydroxyvitamin D[3]) interacts with receptor-containing target cells to produce a lot of responses including long-term regulation of gene activity, that are mediated by nuclear receptors. The nongenomic events include stimulation of Ca{2+} influx, release of Ca{2+} from intracellular stores by phospholipid turnover and activation of phosphorylation cascades. 1'альфа',25-Dihydroxyvitamin D[3] [1,25(OH)[2]D[3]] is a potential therapeutic agent for treatment of many clinical disorders, but its tendency to produce hypercalcemia at therapeutic dosages is a barrier to its usefulness. Derivatives of 1,25(OH)[2]D[3] have been synthesized that possess the beneficial genomic activities of 1,25(OH)[2]D[3] but have reduced nongenomic effects, which may be correlated with a tendency of vitamin D analogs to produce hypercalcemia during long-termtherapy. The discrimination between genomic and nongenomic actions may alllow to predict of which analogues are more likely toproduce beneficial genomic effects, such as reduction of circulating level of PTH, without common side effects, such as hypercalcemia, США, Univ. of Texas, Houston, TX 77030. Библ. 15

ГРНТИ	34.45.21

ВИНИТИ 341.45.21.53.11
Рубрики: ВИТАМИН D
АКТИВНАЯ ФОРМА
ДИГИДРОКСИВИТАМИН D[3]*1'АЛЬФА',25-
АНАЛОГИ
ГЕНОМНЫЕ ЭФФЕКТЫ
КЛЕТКИ-МИШЕНИ
ВНЕГЕНОМНЫЕ ЭФФЕКТЫ
ГИПЕРКАЛЬЦИЕМИЯ
ПОБОЧНЫЕ ЭФФЕКТЫ
ОБЗОРЫ
БИБЛ. 15

Доп.точки доступа:
Devoll, Robert E.

РЖ ВИНИТИ 34 (BI26) 96.08-04М4.483

Farach-Carson, Mary C.
Controlling the nongenomic actions of 1,25(OH)[2]D[3] [Text] / Mary C. Farach-Carson, Robert E. Devoll // News Physiol. Sci. - 1995. - Vol. 10, N oct. - P198-204 . - ISSN 0886-1714
Перевод заглавия: Регулирование внегеномных эффектов 1,25 (OH)[2]D[3]
Аннотация: The active hormonal form of vitamin D (1'альфа', 25-dihydroxyvitamin D[3]) interacts with receptor-containing target cells to produce a lot of responses including long-term regulation of gene activity, that are mediated by nuclear receptors. The nongenomic events include stimulation of Ca{2+} influx, release of Ca{2+} from intracellular stores by phospholipid turnover and activation of phosphorylation cascades. 1'альфа',25-Dihydroxyvitamin D[3] [1,25(OH)[2]D[3]] is a potential therapeutic agent for treatment of many clinical disorders, but its tendency to produce hypercalcemia at therapeutic dosages is a barrier to its usefulness. Derivatives of 1,25(OH)[2]D[3] have been synthesized that possess the beneficial genomic activities of 1,25(OH)[2]D[3] but have reduced nongenomic effects, which may be correlated with a tendency of vitamin D analogs to produce hypercalcemia during long-termtherapy. The discrimination between genomic and nongenomic actions may alllow to predict of which analogues are more likely toproduce beneficial genomic effects, such as reduction of circulating level of PTH, without common side effects, such as hypercalcemia, США, Univ. of Texas, Houston, TX 77030. Библ. 15

ГРНТИ	34.39.41

ВИНИТИ 341.39.41.25.17.17
Рубрики: ВИТАМИН D
АКТИВНАЯ ФОРМА
ДИГИДРОКСИВИТАМИН D[3]*1'АЛЬФА',25-
АНАЛОГИ
ГЕНОМНЫЕ ЭФФЕКТЫ
КЛЕТКИ-МИШЕНИ
ВНЕГЕНОМНЫЕ ЭФФЕКТЫ
ГИПЕРКАЛЬЦИЕМИЯ
ПОБОЧНЫЕ ЭФФЕКТЫ
ОБЗОРЫ
БИБЛ. 15

Доп.точки доступа:
Devoll, Robert E.

РЖ ВИНИТИ 34 (BI27) 96.08-04М6.15

Farach-Carson, Mary C.
Controlling the nongenomic actions of 1,25(OH)[2]D[3] [Text] / Mary C. Farach-Carson, Robert E. Devoll // News Physiol. Sci. - 1995. - Vol. 10, N oct. - P198-204 . - ISSN 0886-1714
Перевод заглавия: Регулирование внегеномных эффектов 1,25 (OH)[2]D[3]
Аннотация: The active hormonal form of vitamin D (1'альфа', 25-dihydroxyvitamin D[3]) interacts with receptor-containing target cells to produce a lot of responses including long-term regulation of gene activity, that are mediated by nuclear receptors. The nongenomic events include stimulation of Ca{2+} influx, release of Ca{2+} from intracellular stores by phospholipid turnover and activation of phosphorylation cascades. 1'альфа',25-Dihydroxyvitamin D[3] [1,25(OH)[2]D[3]] is a potential therapeutic agent for treatment of many clinical disorders, but its tendency to produce hypercalcemia at therapeutic dosages is a barrier to its usefulness. Derivatives of 1,25(OH)[2]D[3] have been synthesized that possess the beneficial genomic activities of 1,25(OH)[2]D[3] but have reduced nongenomic effects, which may be correlated with a tendency of vitamin D analogs to produce hypercalcemia during long-termtherapy. The discrimination between genomic and nongenomic actions may alllow to predict of which analogues are more likely toproduce beneficial genomic effects, such as reduction of circulating level of PTH, without common side effects, such as hypercalcemia, США, Univ. of Texas, Houston, TX 77030. Библ. 15

ГРНТИ	34.39.39

ВИНИТИ 341.39.39.05
Рубрики: ВИТАМИН D
АКТИВНАЯ ФОРМА
ДИГИДРОКСИВИТАМИН D[3]*1'АЛЬФА',25-
АНАЛОГИ
ГЕНОМНЫЕ ЭФФЕКТЫ
КЛЕТКИ-МИШЕНИ
ВНЕГЕНОМНЫЕ ЭФФЕКТЫ
ГИПЕРКАЛЬЦИЕМИЯ
ПОБОЧНЫЕ ЭФФЕКТЫ
ОБЗОРЫ
БИБЛ. 15

Доп.точки доступа:
Devoll, Robert E.

РЖ ВИНИТИ 76 (BI31) 96.08-04Т3.100

Farach-Carson, Mary C.
Controlling the nongenomic actions of 1,25(OH)[2]D[3] [Text] / Mary C. Farach-Carson, Robert E. Devoll // News Physiol. Sci. - 1995. - Vol. 10, N oct. - P198-204 . - ISSN 0886-1714
Перевод заглавия: Регулирование внегеномных эффектов 1,25 (OH)[2]D[3]
Аннотация: The active hormonal form of vitamin D (1'альфа', 25-dihydroxyvitamin D[3]) interacts with receptor-containing target cells to produce a lot of responses including long-term regulation of gene activity, that are mediated by nuclear receptors. The nongenomic events include stimulation of Ca{2+} influx, release of Ca{2+} from intracellular stores by phospholipid turnover and activation of phosphorylation cascades. 1'альфа',25-Dihydroxyvitamin D[3] [1,25(OH)[2]D[3]] is a potential therapeutic agent for treatment of many clinical disorders, but its tendency to produce hypercalcemia at therapeutic dosages is a barrier to its usefulness. Derivatives of 1,25(OH)[2]D[3] have been synthesized that possess the beneficial genomic activities of 1,25(OH)[2]D[3] but have reduced nongenomic effects, which may be correlated with a tendency of vitamin D analogs to produce hypercalcemia during long-termtherapy. The discrimination between genomic and nongenomic actions may alllow to predict of which analogues are more likely toproduce beneficial genomic effects, such as reduction of circulating level of PTH, without common side effects, such as hypercalcemia, США, Univ. of Texas, Houston, TX 77030. Библ. 15

ГРНТИ	76.31.29

ВИНИТИ 761.31.29.02.43
Рубрики: ВИТАМИН D
АКТИВНАЯ ФОРМА
ДИГИДРОКСИВИТАМИН D[3]*1'АЛЬФА',25-
АНАЛОГИ
ГЕНОМНЫЕ ЭФФЕКТЫ
КЛЕТКИ-МИШЕНИ
ВНЕГЕНОМНЫЕ ЭФФЕКТЫ
ГИПЕРКАЛЬЦИЕМИЯ
ПОБОЧНЫЕ ЭФФЕКТЫ
ОБЗОРЫ
БИБЛ. 15

Доп.точки доступа:
Devoll, Robert E.

"Электронные каталоги и базы данных библиотек СО РАН"

© Международная Ассоциация пользователей и разработчиков электронных библиотек и новых информационных технологий
(Ассоциация ЭБНИТ)

rtvarBDview(" результаты поиска","20190607010228","4682442");

Вид поиска